產品簡介:骨質疏鬆症 - 具有高潛力備受期待的新藥候補

產品簡介:骨質疏鬆症 - 具有高潛力備受期待的新藥候補 是由出版商Datamonitor在2011年11月所出版的。 這份英文市場調查報告書包含Pages: 208 價格從美金11400起跳。

簡介

本報告提供隨著患者人數增加而展現出潛在高收益性的骨質疏鬆症治療藥物市場相關資料，已上市販售的治療藥物及開發平台相關調查分析，將其結果，概述為以下內容。

概要

• 觸媒
• 要旨

執行摘要

• 策略性範圍界定及其焦點
• 主要結果
• 相關報告書

市場定義及概要

• 產品概要

市販產品概要

• Fosamax/Fosamax Plus D (alendronate，Merck & Co.)
• Actonel/Actonel with Calcium(risedronic acid，Sanofi/Warner Chilcott)
• Bonviva/Boniva(ibandronic acid，Roche/GlaxoSmithKline)
• Aclasta/Reclast(zoledronic acid，Novartis)
• Foruteo(teriparatide，Eli Lilly)
• Prolia(denosumab，Amgen/GlaxoSmithKline/第一三共)
• Evista(raloxifene，Eli Lilly)
• Conbriza/Viviant (bazedoxifene，Pfizer/Almirall)
• Protelos(strontium ranelate，Servier)
• Edirol (eldecalcitol，中外製藥/大正製藥)
• 其他骨質疏鬆症治療藥物

開發中產品概要

• Odanacatib (MK0822; Merck & Co.)
• ZT-031 (hPTH1-31; Zelos Therapeutics)
• ZP-PTH (hPTH1-34; Zosano Pharma)
• BA058 (PTH peptide fragment; Radius)
• EX101 (alendronate; EffRx/Nycomed)
• Almerol (alendronate; Merrion)
• Aprela (bazedoxifene with conjugated estrogens; Pfizer)
• SMC021 (salmon calcitonin; Novartis)
• Capsitonin (BN-002; Bone Medical)
• NBS101 (strontium malonate; Osteologix)
• 其他開發中的骨質疏鬆症治療藥物

參考文獻

附表

目錄

Description

Introduction

Despite major brands losing market exclusivity increasing cost competition, the osteoporosis market remains attractive. Leading osteoporosis companies continue to promote their products and develop their franchises while drug developers strive to bring their agents to market in an attempt to meet unmet need and tap into this potentially profitable patient population

Features and benefits

• Understand Datamonitor's independent appraisal of marketed brands and key pipeline agents indicated for treating osteoporosis
• Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes
• Understand how marketed brands are positioned in the osteoporosis treatment algorithm and how they are perceived by treating physicians
• Evaluate the latest drug launches and barriers to increasing market share
• Determine to what extent future therapies satisfy the main clinical unmet needs in osteoporosis treatment

Highlights

• Forteo (teriparatide; Eli Lilly) further increased its class leading position after its launch in Japan in summer 2010. The biggest opportunity in the market remains for new safe and efficacious anabolic therapies, indeed several PTH analogs continue their development, in an attempt to become the first second generation PTH to reach the market.
• n 2010, Prolia (denosumab) was launched in the US and EU. Initial sales were modest and Amgen and its European partner GlaxoSmithKline need to continue marketing their product aggressively as a convenient bone strengthening drug in order to increase market share.
• Odanacatib (Merck & Co) is the most promising product in the pipeline due to its favorable clinical profile and Merck's market experience. However, with launch is expected only in 2015, Merck will face the large challenge of penetrating the highly saturated and genericized antiresorptive market.

Your key questions answered

• What are the key differentiating features of approved therapies for osteoporosis and how are they used in the daily management of the disease?
• How did Prolia perform upon launch and what strategies are Amgen and GlaxoSmithKline implementing to drive market penetration
• How do key opinion leaders and prescribers perceive available treatments for osteoporosis?
• Do pipeline products address key clinical unmet needs?
• What are the comparative strengths and weaknesses of the key osteoporosis brands and pipeline candidates?

TOC

Executive Summary

• Update details: November 2011
• Strategic scoping and focus
• Datamonitor key findings
• Related reports

OVERVIEW

• Catalyst
• Summary

MARKET DEFINITION AND OVERVIEW

• Product overview

MARKETED PRODUCT PROFILES

• Fosamax/Fosamax Plus D (alendronate; Merck & Co.)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Physician perception of Fosamax
• Clinical and commercial attractiveness
• Actonel/Actonel with Calcium (risedronic acid; Sanofi/Warner Chilcott)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Physician perception of Actonel
• Clinical and commercial attractiveness
• Bonviva/Boniva (ibandronic acid; Roche/GlaxoSmithKline)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Physician perception of Bonviva
• Clinical and commercial attractiveness
• Aclasta/Reclast (zoledronic acid; Novartis)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Physician perception of Aclasta
• Clinical and commercial attractiveness
• Forteo (teriparatide; Eli Lilly)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Physician perception of Forteo
• Clinical and commercial attractiveness
• Prolia (denosumab; Amgen/GlaxoSmithKline/Daiichi Sankyo)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Clinical and commercial attractiveness
• Evista (raloxifene; Eli Lilly)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Physician perception of Evista
• Clinical and commercial attractiveness
• Conbriza/Viviant (bazedoxifene; Pfizer/Almirall)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Clinical and commercial attractiveness
• Protelos (strontium ranelate; Servier)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Physician perception of Protelos
• Clinical and commercial attractiveness
• Edirol (eldecalcitol; Chugai/Taisho)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Clinical and commercial attractiveness
• Other marketed drugs for osteoporosis
• Bonoteo/Recalbon (minodronic acid; Astellas/Ono Pharmaceutical)
• Preotact (full-length PTH 1-84; NPS/Nycomed)
• Miacalcic (calcitonin-salmon; Novartis)
• Fortical (calcitonin-salmon; UniGene)

PIPELINE PRODUCT PROFILES

• Odanacatib (MK0822; Merck & Co.)
• Drug profile
• Development overview
• SWOT analysis
• Satisfaction of unmet needs
• Clinical and commercial attractiveness
• ZT-031 (hPTH1-31; Zelos Therapeutics)
• Drug profile
• Development overview
• SWOT analysis
• Satisfaction of unmet needs
• Clinical and commercial attractiveness
• ZP-PTH (hPTH1-34; Zosano Pharma/ Asahi Kasei)
• Drug profile
• Development overview
• SWOT analysis
• Satisfaction of unmet needs
• Clinical and commercial attractiveness
• BA058 (PTH peptide fragment; Radius)
• Drug profile
• Development overview
• SWOT analysis
• Satisfaction of unmet needs
• Clinical and commercial attractiveness
• EX101 (alendronate; EffRx/Nycomed)
• Drug profile
• SWOT analysis
• Satisfaction of unmet needs
• Clinical and commercial attractiveness
• Aprela (bazedoxifene with conjugated estrogens; Pfizer)
• Drug profile
• Development overview
• SWOT analysis
• Satisfaction of unmet needs
• Clinical and commercial attractiveness
• SMC021 (oral salmon calcitonin; Novartis)
• Drug profile
• Development overview
• SWOT analysis
• Satisfaction of unmet needs
• Clinical and commercial attractiveness
• Ostora (oral salmon calcitonin; Tarsa)
• Drug pro

相關商品

骨頭疾病治療相關市場調查報告書

全球及中國的骨質疏鬆症治療藥物市場:市場規模·市場趨勢·市場預測(2010-2015年)
Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
價格 : US $ 2395
出版日期 : 2012年01月

中國的骨質疏鬆症市場分析與預測(2007年∼2015年)
China Osteoporosis Market Analysis and Forecast, 2007 - 2015
價格 : US $ 1500
出版日期 : 2012年01月

全球肌肉骨骼疾病治療藥物的市場(到2017年為止)
Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
價格 : US $ 3500
出版日期 : 2012年01月

Datamonitor發行的製藥相關市場調查報告書

美國及EU主要5個國家的HIV藥市場:市場預測

HIV Market Forecast

價格 : US $ 11400

出版日期 : 2012年02月

市場及產品預測:HIV - 患病人口的擴大與新STR劇增的歐美銷售

Market and Product Forecasts: HIV - Rising prevalence and novel STRs boost sales in the US and Europe

價格 : US $ 11400

出版日期 : 2012年02月

FDA的Bydureon的認證:醫生的見解

Bydureon FDA Approval: Physician Opinion

價格 : US $ 3800

出版日期 : 2012年02月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!